Key Investor Signals
Secured commercial partnership with Viscofan BioEngineering
The June 2025 partnership covers marketing Fibercoll-Flex collagen bioink and joint work on 3D tissue-model applications.
Added ZHAW 3D-tissue leader as scientific adviser
Markus Rimann, head of ZHAW's 3D Tissues and Biofabrication group, joined Asemblis as scientific adviser to support its preclinical-model roadmap.
CEO brings REGENHU bioprinting commercialization experience
Before Asemblis, Caio Valeriano was Sales Manager at REGENHU, where he worked on commercializing advanced bioprinting technology.
Other Positive Signals
- Received Venture Kick Stage 1 funding in October 2026 to support market access and partnerships for its obesity research platform.
- Selected for SLAS's 2026 Startup Pitch Showcase at Swiss Biotech Day.
- Asemblis is listed as a member of the Swiss Biotech Association.
Team
Caio Valeriano
CEO, CSO and Founder
- Former Sales Manager at REGENHU, a Swiss company developing bioprinting systems for research and drug development.
- Helped commercialize REGENHU's Dynamic Formulation Module, a CSEM co-developed system for multi-material bioprinting.
- Biomedical Sciences graduate from the Federal University of Goiás, where his thesis focused on biomaterials for an artificial-heart project.
Product
Asemblis is building biofabricated human fat-tissue models for obesity and metabolic-disease research. The goal is to give metabolic R&D teams more human-relevant data earlier in preclinical development.
3D human fat-tissue models
Asemblis builds biofabricated models designed to mimic human fat tissue more closely, giving metabolic R&D teams a human-relevant system for preclinical research.
Models for obesity biology
The models are intended to investigate questions that standard preclinical systems struggle to answer, including inflammation, weight regain, muscle loss and safety signals.
Scoped feasibility studies
Industry partners can scope feasibility studies or pilots around a defined research question, with endpoints, deliverables and terms agreed before work begins.
Market Overview
Obesity affects more than 1 billion people worldwide, including 890 million adults in 2022. The category is already commercially significant: Novo Nordisk generated DKK 82.3 billion in obesity-care sales in 2025, while branded GLP-1 obesity-market volume grew 104% in the same year.
Preclinical translation remains a major bottleneck in drug development. The FDA says more than 90% of drugs that clear animal studies do not receive approval, often because safety or efficacy problems emerge in human trials. In 2026, the agency highlighted advanced in vitro systems and other human-derived methods as ways to improve prediction of drug effects.
WHO estimate of people living with obesity worldwide in 2022.
Novo Nordisk's obesity-care sales in 2025, up 26% from 2024.
Volume growth in the global branded GLP-1 obesity market in 2025, according to Novo Nordisk.
Share of drugs that clear animal studies but still do not receive FDA approval.
Comparable Outcomes
MatTek
MatTek developed lab-grown human tissue models for clinical and preclinical testing, including 3D tissues used as human-relevant alternatives to animal models. CELLINK acquired MatTek in March 2021 for $68 million in cash.
Visikol
Visikol provided pharma and biotech companies with 3D cell-culture assays, tissue imaging and digital pathology through a contract research model. CELLINK acquired Visikol in May 2021 for $7.5 million in cash.
Interested in More Startups Like Asemblis?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.